|

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

RECRUITINGPhase 2Sponsored by Zagazig University
Actively Recruiting
PhasePhase 2
SponsorZagazig University
Started2022-04-03
Est. completion2025-10-03
Eligibility
Age9 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05291845

Summary

To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy

Eligibility

Age: 9 Years+Healthy volunteers accepted
Inclusion Criteria:

* patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study

Exclusion Criteria:

* Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine

Conditions3

CancerHuman Papilloma VirusWarts

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.